DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20191587

A study on cisplatin -paclitaxel induced peripheral neuropathy in cancer patients

Umamaheshwari C., Shanthi M., Malathi M.

Abstract


Background: Chemotherapy induced peripheral neuropathy is a significant disability after the treatment of large number of cancers and they have an impact on quality of life. The aim of the present endeavour was to study the cisplatin-paclitaxel induced peripheral neuropathy in patients with lung or ovarian cancer

Methods: The study was carried out in the Department of Oncology, Government Rajaji Hospital, Madurai, after obtaining clearance from Institutional ethical committee, Government Rajaji Hospital, Madurai. Thirty newly diagnosed patients suffering from Lung or ovarian cancer attending Oncology department were selected. After satisfying inclusion and exclusion criteria. Patient received injection cisplatin 60 mg/m2 and injection paclitaxel 175 mg/m2. Nerve conduction study was done to assess the peripheral neuropathy. It was done before starting the chemotherapy. Patients with grade 0 neuropathy were included for the study. Nerve conduction study was repeated after each cycle. The time taken to develop peripheral neuropathy was assessed using Cancer Institute - Common Toxicity Criteria version 3.0. The data were analyzed with SPSS statistical software package (Version 16.0 SPSS Inc., Chicago, USA ).

Results: There is a statistically significant reduction in sensory nerve (sural) amplitude (SNAP) and latency (p <0.05) indicating significant axonal damage. The time taken to develop peripheral neuropathy was 3 cycles with grade 3/4.

Conclusions: In this present study, the neurotoxicity induced by cisplatin-paclitaxel in patients with lung or ovarian carcinoma was observed, so that early intervention can prevent the permanent neurotoxicity.


Keywords


Cisplatin, Chemotherapy, Nerve conduction study, Neurotoxicity, Paclitaxel, Peripheral neuropathy

Full Text:

PDF

References


Dropcho EJ. Remote neurological manifestations of cancer. Neurologic Clin. 2002;20(1)85-122.

Jaman P, Neurological disease peripheral nerve disease. In:Parveenkumar & Michaelclark. Kumar & clark clinical medicine. 8th ed. Spain: Saunders Elsevier;2012:148.

Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL, Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther. 2010 Mar-Apr;17(2):148-58.

Leach JP, Davemport RJ disease of peripheral neuropathy, neurological disease. In: Brain R. Walker. Davidsons principle & practice of medicine. 22nd ed. China: Lippincott Williams & Wilkins Elsevier; 2015:1223-1226.

Eric P Widmaier, Hershal Raff. Neural signalling and the structure of nervous system in Vanders Human physiology. 11th ed. New York: McGraw hill; 2008:138.

Hilkens PH, Pronk LC, Verweij J, Vecht CH, Van Putten WL, Van Den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Brit J Canc. 1997 Feb;75(3):417.

Lisa M, De Angelis, Patrick y Wen, Primary and metastatic tumors of the nervous system In:Longo, fauci. Harrisons Neurology in Clinical medicine. 3rd edition. China: McGraw Hill; 2013:438.

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012 Apr 1;82(1):51-77.

Daugaard GK, Petrera J, Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cisā€platin. Acta Neurologica Scandinavica. 1987;76(2):86-93.

Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27-46.